(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.36%) $78.39
(0.33%) $2.15
(0.39%) $2 317.50
(1.69%) $27.14
(-0.31%) $962.35
(0.00%) $0.929
(-0.09%) $10.86
(0.01%) $0.797
(0.00%) $91.45
Quarter results tomorrow
(amc 2024-05-07)
Expected move: +/- 11.77%
Live Chart Being Loaded With Signals
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases...
Stats | |
---|---|
今日成交量 | 185 552 |
平均成交量 | 407 946 |
市值 | 63.28M |
EPS | $-0.220 ( 2024-05-02 ) |
下一个收益日期 | ( $-0.190 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.600 |
ATR14 | $0.00900 (1.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-01 | Mcclure Matthew W. | Buy | 72 000 | Stock Option (Right to Buy) |
2024-03-01 | Calhoun Lesley Ann | Buy | 308 940 | Stock Option (Right to Buy) |
2024-03-01 | Symons Julian A. | Buy | 72 000 | Stock Option (Right to Buy) |
2024-03-01 | Blatt Lawrence | Buy | 965 435 | Stock Option (Right to Buy) |
2024-02-28 | Hirth Peter | Buy | 4 411 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
82.22 |
Last 96 transactions |
Buy: 18 924 669 | Sell: 1 675 487 |
音量 相关性
Aligos Therapeutics, Inc. 相关性 - 货币/商品
Aligos Therapeutics, Inc. 财务报表
Annual | 2023 |
营收: | $15.53M |
毛利润: | $12.46M (80.24 %) |
EPS: | $-1.360 |
FY | 2023 |
营收: | $15.53M |
毛利润: | $12.46M (80.24 %) |
EPS: | $-1.360 |
FY | 2022 |
营收: | $13.91M |
毛利润: | $10.23M (73.57 %) |
EPS: | $-2.25 |
FY | 2021 |
营收: | $4.36M |
毛利润: | $4.36M (100.00 %) |
EPS: | $-3.22 |
Financial Reports:
No articles found.
Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。